Windlas Biotech Ltd. (IN:WINDLAS)
:WINDLAS
WINDLAS Stock Chart & Stats
₹788.05
₹26.85(2.61%)
At close: 4:00 PM EST
₹788.05
₹26.85(2.61%)
Day’s Range― - ―
52-Week Range₹699.35 - ₹1,137.60
Previous CloseN/A
Volume34.51K
Average Volume (3M)3.48K
Market Cap
₹16.16B
Enterprise Value₹16.56B
Total Cash (Recent Filing)₹2.61B
Total Debt (Recent Filing)₹312.09M
Price to Earnings (P/E)27.9
Beta0.88
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.71%
Share Statistics
EPS (TTM)7.12
Shares Outstanding21,165,873
10 Day Avg. Volume3,282
30 Day Avg. Volume3,478
Financial Highlights & Ratios
PEG Ratio8.12
Price to Book (P/B)4.20
Price to Sales (P/S)2.80
P/FCF Ratio132.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent top-line expansion reflects durable demand for Windlas’s finished-dose and CDMO services. Revenue growth driven across periods supports scale economies, broader client engagement, and provides headroom to invest in capacity, R&D, and commercial reach over the next 2–6 months.
Improving Profit MarginsRising gross and EBITDA margins point to better pricing, mix improvement, and operational leverage in manufacturing. Sustained margin expansion increases internal cash generation and resilience to input-cost shocks, supporting reinvestment and competitive pricing over the coming quarters.
Conservative Leverage / Strong EquityA low debt profile and healthy equity base reduce refinancing and solvency risk while enabling strategic investments or capacity expansion without stressing cash flow. Conservative leverage supports stability through industry cycles and preserves financial optionality for partnerships or M&A.
Bears Say
Declining Operating Cash FlowWhile cash generation remains positive, a YoY decline in operating cash flow and volatile free cash flow growth can constrain consistent funding for capex, working capital needs, or dividend increases. This volatility may limit strategic flexibility in the medium term.
Rising Total LiabilitiesA measured rise in liabilities, even from a low base, could signal growing working-capital stress or contingent obligations. If liabilities continue upward, it could pressure liquidity metrics and restrict the company’s conservative financing posture over the next several quarters.
Moderate EBIT Margin ImprovementSlower improvement in EBIT margin versus gross/EBITDA gains suggests remaining fixed-cost or SG&A inefficiencies. Without further operational tightening, EBIT growth may lag revenue, limiting scalability of profits and cash conversion as volumes expand in the medium term.
Windlas Biotech Ltd. News
WINDLAS FAQ
What was Windlas Biotech Ltd.’s price range in the past 12 months?
Windlas Biotech Ltd. lowest stock price was ₹699.35 and its highest was ₹1137.60 in the past 12 months.
What is Windlas Biotech Ltd.’s market cap?
Windlas Biotech Ltd.’s market cap is ₹16.16B.
When is Windlas Biotech Ltd.’s upcoming earnings report date?
Windlas Biotech Ltd.’s upcoming earnings report date is May 27, 2026 which is in 50 days.
How were Windlas Biotech Ltd.’s earnings last quarter?
Windlas Biotech Ltd. released its earnings results on Feb 05, 2026. The company reported ₹7.118 earnings per share for the quarter, beating the consensus estimate of N/A by ₹7.118.
Is Windlas Biotech Ltd. overvalued?
According to Wall Street analysts Windlas Biotech Ltd.’s price is currently Overvalued.
Does Windlas Biotech Ltd. pay dividends?
Windlas Biotech Ltd. pays a Annually dividend of ₹5.8 which represents an annual dividend yield of 0.71%. See more information on Windlas Biotech Ltd. dividends here
What is Windlas Biotech Ltd.’s EPS estimate?
Windlas Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Windlas Biotech Ltd. have?
Windlas Biotech Ltd. has 21,165,873 shares outstanding.
What happened to Windlas Biotech Ltd.’s price movement after its last earnings report?
Windlas Biotech Ltd. reported an EPS of ₹7.118 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.123%.
Which hedge fund is a major shareholder of Windlas Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:WINDLAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Windlas Biotech Ltd.
Windlas Biotech Limited operates as a contract development and manufacturing organization (CDMO). Its CDMO services include product discovery, product development, licensing, and commercial manufacturing generic products, including generic products. The company provides its CMDO products and services across a range of pharmaceutical and nutraceutical conventional, and novel products for customers who market such products under their own brand names to the end users. It also offers manufactures various domestic trade generics and over-the-counter brand product portfolio to cater to nutritional, ayurvedic, wellness, and personal care markets. The company's domestic trade generics and OTC brands products are distributed through the offline channel, such as distributors, stockists, retail pharmacies, and institutional tenders, as well as the online channel, such as various e-commerce platforms. It exports its products primarily to Vietnam, Myanmar, Sri Lanka, Thailand, the Philippines, Cambodia, Fiji, Trinidad & Tobago, and South Africa. The company was incorporated in 2001 and is based in Gurugram, India.
Technical Analysis
Bajaj Healthcare Ltd
―
Beta Drugs Ltd.
―
Indoco Remedies Limited
―
Sakar Healthcare Ltd
―
SMS Pharmaceuticals Limited
―